Social Media Ideas for Gilead Sciences

WHO and Gilead Sciences renew partnership to accelerate visceral leishmaniasis elimination

The World Health Organization (WHO) and Gilead Sciences have renewed their partnership through a new five-year agreement (2026–2030) to support the elimination of visceral leishman...

Gilead: 'Hold' On Biktarvy Sales Growth And MM Drug Development Program

<![CDATA[Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson &...

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’

The German biotech shared updated data from a phase 1 study of the antibody-drug conjugate TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront e...

Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

leadership change at gilead

leadership change at gilead Anonymous (not verified) Mon, 05/18/2026 - 08:33 field_thread_url https://cafepharma.com/boards/threads/leadership-change-at-gi...

GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript

Gilead Owed $68M In Counterfeit Case, Magistrate Judge Says

A New York federal magistrate judge has recommended awarding $68 million to biopharmaceutical company Gilead Sciences Inc. from a group of companies it accused of producing counter...

Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field

Gilead has abandoned work on the lead rheumatoid arthritis drug from its $405 million buyout of MiroBio in the latest blow to the BTLA agonist field.

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

Pharmacies Hit With Injunction In Gilead Counterfeit Drug Row

A New York federal judge has issued a preliminary injunction blocking a pair of Queens pharmacies from selling any human immunodeficiency virus medications that bear the Gilead nam...

Mapp, Gilead antivirals to be deployed in DRC Ebola trial: WHO chief

Officials are planning to study Mapp Biopharmaceutical’s MBP134 and Gilead Sciences’ remdesivir, which gained prominence during the COVID-19 pandemic, against the Bundibugyo ebolav...

<![CDATA[Ascidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editors]]>

<![CDATA[AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal]]>

New FDA Nod Keeps Gilead Drug Competitive With AstraZeneca & Daiichi in Breast Cancer

Gilead Sciences antibody drug conjugate Trodelvy is now approved as a first-line treatment for triple-negative breast cancer. This expanded approval for Trodelvy comes with a sligh...

GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease

GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients across two trials were...

FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services

Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brough...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Hepcludex]]>

<![CDATA[GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc. ]]>

Prep Matrix Teams

Prep Matrix Teams Anonymous (not verified) Sun, 05/24/2026 - 11:37 field_thread_url https://cafepharma.com/boards/threads/prep-matrix-teams.709671/...

<![CDATA[Parabilis Medicines Raises $670 Million in Initial Public Offering ]]>

Agenus surges on study pivot; Apnimed lines up an IPO

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA...